This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acura Pharma: FDA Panel Live Blog

Acura Pharmaceuticals (ACUR - Get Report) brings its abuse-resistant painkiller Acurox in front of an advisory committee of the U.S. Food and Drug Administration today.

Acurox is a short-acting drug that consists of the powerful painkiller oxycodone combined with niacin and other ingredients that Acura says deters common methods of prescription drug tampering and abuse. King Pharmaceuticals (KG) is Acura's marketing partner.

FDA convened today's panel to get outside input on Acurox because the agency has concerns about the use of niacin to deter abuse. In briefing documents released Tuesday, FDA reviewers concluded that, "niacin offers little in the way of deterrence to oral abuse," in part because the aversive effects of niacin can be defeated if a person eats a high-fat meal or takes aspirin.

The advisory panel will also be asked to consider whether the side effects of niacin -- mainly flushing, headaches and chills -- are a risk for patients who take Acurox according to their doctor's instructions.

Acura believes that opioid abuse is a major public health problem and for that reason, Acurox was designed to relieve moderate-to-severe pain and minimize the potential for opioid abuse by the three most common methods: oral (when taken at doses higher than recommended); intranasal (nasally snorting crushed tablets); and intravenous (IV injection of dissolved tablets).

For those interested, briefing documents for today's Acura FDA meeting, including the FDA's review and Acura's presentation, can be found on the FDA's web site.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACUR $2.35 -0.84%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.15 -0.02%
TSLA $229.64 5.22%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs